Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin d trial aims to shield kidneys in critical illness

NCT ID NCT02962102

Prevention Sponsor: David Leaf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving activated vitamin D (calcifediol and calcitriol) to critically ill patients in the ICU could prevent or lessen acute kidney injury (AKI). Researchers enrolled 150 adults at high risk for AKI. The goal was to see if this treatment could reduce deaths, the need for dialysis, and kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

150 people

The number who actually took part.

Started

Apr 2017

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Admitted to the ICU within 48h prior to enrollment * Likely to remain in the ICU (alive) for ≥72h * Naso/orogastric tube or ability to swallow * High risk of severe AKI Exclusion Criteria: * Serum total calcium \> 9.0 mg/dl or phosphate \> 6.0 mg/dL within previous 48h * Currently receiving oral calcium supplementation * Ingestion of vitamin D3 \>1,000 IU/day or any 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D during the previous 7 days * AKI stage 2 or 3 (based on KDIGO serum creatinine and/or urine output criteria) * History of transplantation or receiving chronic (\>7days) of immunosuppressive medications (not including glucocorticoid steroids at a dose less than or equivalent to prednisone 20 mg/day) * Neutropenia in the previous 48h * Active primary parathyroid disease, active granulomatous disease, or symptomatic nephrolithiasis in the previous 3 months * Receiving cytochrome P450 inhibitors * Chronic Kidney Disease stage V or End Stage Renal Disease * Hemoglobin \< 7 g/dL * GI malabsorption * Prisoner * Pregnancy or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Critically ill

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.